Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniques

被引:81
作者
Saldanha, J
Lelie, N
Yu, MW
Heath, A
机构
[1] Natl Inst Biol Standards & Controls, Div Virol, S Mimms EN6 30J, Herts, England
[2] CLB, Amsterdam, Netherlands
[3] FDA, CBER, Div Hematol, Bethesda, MD USA
[4] Natl Inst Biol Standards & Controls, Infomat Div, S Mimms EN6 30J, Herts, England
关键词
human parvovirus B19; International Standard; NAT assays; WHO collaborative study;
D O I
10.1046/j.1423-0410.2002.00132.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives A collaborative study, involving 26 laboratories from 14 countries, was carried out in order to establish a World Health Organization (WHO) International Standard for human parvovirus B19 (B19) DNA nucleic acid amplification techniques (NAT). Materials and methods Four samples: AA, BB (which were lyophilized), CC and DD (which were liquid preparations) were analysed using several different NAT assays. The mean B19 DNA content of each sample was determined for each laboratory using an end-point dilution method. Results There was good agreement between the overall mean 'equivalents'/ml obtained by the different assays. The mean log(10) 'equivalents'/ml were 5.76 for sample AA, 5.73 for sample BB, 5.82 for sample CC and 7.70 for sample DD. The differences in titre among samples AA, BB and CC were not statistically significant, but the titre of DD was significantly higher. Conclusions Despite the range of NAT assays used in the study, it was possible to calculate the mean B19 DNA concentrations in the four preparations. Lyophilized preparation AA was established as the first International Standard for B19 DNA NAT assays and was assigned a concentration of 10(6) international units (IU)/ml.
引用
收藏
页码:24 / 31
页数:8
相关论文
共 20 条
  • [1] DETECTION OF ANTIBODIES AND ANTIGENS OF HUMAN PARVOVIRUS B19 BY ENZYME-LINKED-IMMUNOSORBENT-ASSAY
    ANDERSON, LJ
    TSOU, C
    PARKER, RA
    CHORBA, TL
    WULFF, H
    TATTERSALL, P
    MORTIMER, PP
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1986, 24 (04) : 522 - 526
  • [2] ANDRSON LJ, 1988, J INFECT DIS, V161, P603
  • [3] Large-scale screening for human parvovirus B19 DNA by PCR: Application to the quality control of plasma for fractionation
    Aubin, JT
    Defer, C
    Vidaud, M
    Montreuil, MM
    Flan, B
    [J]. VOX SANGUINIS, 2000, 78 (01) : 7 - 12
  • [4] Brown Kevin E., 2001, Transfusion (Bethesda), V41, P130, DOI 10.1046/j.1537-2995.2001.41010130.x
  • [5] THE PREVALENCE OF ANTIBODY TO HUMAN PARVOVIRUS-B19 IN ENGLAND AND WALES
    COHEN, BJ
    BUCKLEY, MM
    [J]. JOURNAL OF MEDICAL MICROBIOLOGY, 1988, 25 (02) : 151 - 153
  • [6] Davenport R, 2000, BLOOD, V96, p451A
  • [7] FRANCIS B, 1993, GLIM SYSTEM
  • [8] Transmission of symptomatic parvovirus B19 infection by fibrin sealant used during surgery
    Hino, M
    Ishiko, O
    Honda, KI
    Yamane, T
    Ohta, K
    Takubo, T
    Tatsumi, N
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2000, 108 (01) : 194 - 195
  • [9] An international collaborative study to establish the 1st international standard for HIV-1 RNA for use in nucleic acid-based techniques
    Holmes, H
    Davis, G
    Heath, A
    Hewlett, I
    Lelie, N
    [J]. JOURNAL OF VIROLOGICAL METHODS, 2001, 92 (02) : 141 - 150
  • [10] B19 PARVOVIRUS DNA IN SOLVENT DETERGENT-TREATED ANTI-HEMOPHILIA CONCENTRATES
    LEFRERE, JJ
    MARIOTTI, M
    THAUVIN, M
    [J]. LANCET, 1994, 343 (8891) : 211 - 212